Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Makoto Okawaki is active.

Publication


Featured researches published by Makoto Okawaki.


Cancer Research | 2015

Abstract 1757: The new molecular target therapy of Hsp90 inhibition in esophageal squamous cell carcinoma

Masahiro Yamamura; Tsutomu Nohno; Akira Yamauchi; Naoki Katase; Makoto Okawaki; Akira Sawaki; Hideo Matsumoto; Toshihiro Hirai; Yoshiyuki Yamaguchi

Heat shock protein 90 (HSP90) has numerous cellular functions, including promotion of proper protein folding, and stabilizes a number of oncogenic proteins, many of which are overexpressed in cancers. The objective of this study is to evaluate an antitumor effect of HSP90 inhibitor, AUY922, in esophageal squamous cell carcinoma(ESCC) cell lines. ESCC cell lines were treated with AUY922 to examine the effect on proliferation assay, apoptosis assay, Western blotting, and chemotaxis assay. AUY922 inhibited cell proliferation in ESCC cells in a dose- and time-dependent manner. Growth inhibitory effect of AUY922 for ESCC cells was higher than CDDP. With flowcytometry and immunostaining, we showed that AUY922 induced apoptosis in ESCC cells and inhibited chemotaxis of ESCC cells. These antitumor effects of AUY922 were due to inhibition of cell proliferation through suppression of phosphorylation of the client proteins. The HSP90 inhibitor is useful as an antitumor drug in ESCC by inhibiting proliferation of ESCC cells through novel mechanism. Citation Format: Masahiro Yamamura, Tsutomu Nohno, Akira Yamauchi, Naoki Katase, Makoto Okawaki, Akira Sawaki, Hideo Matsumoto, Toshihiro Hirai, Yoshiyuki Yamaguchi. The new molecular target therapy of Hsp90 inhibition in esophageal squamous cell carcinoma. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 1757. doi:10.1158/1538-7445.AM2015-1757


International Journal of Oncology | 1992

Targeting of CD4+CD25high cells while preserving CD4+CD25low cells with low-dose chimeric anti-CD25 antibody in adoptive immunotherapy of cancer.

Riki Okita; Yoshiyuki Yamaguchi; Masahiro Ohara; Katsuji Hironaka; Makoto Okawaki; Ichiro Nagamine; Takuhiro Ikeda; Akiko Emi; Jun Hihara; Morihito Okada


Oncology Reports | 2006

Postoperative immunosuppression cascade and immunotherapy using lymphokine-activated killer cells for patients with esophageal cancer: Possible application for compensatory anti-inflammatory response syndrome

Yoshiyuki Yamaguchi; Jun Hihara; Katsuji Hironaka; Akiko Ohshita; Riki Okita; Makoto Okawaki; Kazuo Matsuura; Ichiro Nagamine; Takuhiro Ikeda; Masahiro Ohara; Yoichi Hamai


Anticancer Research | 2005

Feasibility Study of Adoptive Immunotherapy for Metastatic Lung Tumors Using Peptide-pulsed Dendritic Cell-activated Killer (PDAK) Cells

Yoshiyuki Yamaguchi; Koji Ohta; Yoshiharu Kawabuchi; Akiko Ohshita; Riki Okita; Makoto Okawaki; Katsuji Hironaka; Kazuo Matsuura; Tetsuya Toge


Anticancer Research | 2006

Essential Requirement of Toll-like Receptor 4 Expression on CD11c+ Cells for Locoregional Immunotherapy of Malignant Ascites Using a Streptococcal Preparation OK-432

Katsuji Hironaka; Yoshiyuki Yamaguchi; Riki Okita; Makoto Okawaki; Ichiro Nagamine


Anticancer Research | 2005

HER2-specific cytotoxic activity of lymphokine-activated killer cells in the presence of trastuzumab

Yoshiyuki Yamaguchi; Katsuji Hironaka; Makoto Okawaki; Riki Okita; Kazuo Matsuura; Akiko Ohshita; Tetsuya Toge


Hiroshima journal of medical sciences | 2008

Dose-Finding Study of Anti-CD25 Antibody for Targeting Regulatory T Cells in Locoregional Immunotherapy of Malignant Effusion

Makoto Okawaki; Yoshiyuki Yamaguchi; Riki Okita; Masahiro Ohara; Morihito Okada


Internal Medicine | 2011

A Case of Stroke due to Tumor Emboli Associated with Metastatic Cardiac Liposarcoma

Mutsumi Mitomi; Kazumi Kimura; Yasuyuki Iguchi; Akihiro Hayashida; Hirotake Nishimura; Isao Irei; Makoto Okawaki; Hiroaki Ikeda


Anticancer Research | 2016

A Prospective Observational Study of Adoptive Immunotherapy for Cancer Using Zoledronate-Activated Killer (ZAK) Cells – An Analysis for Patients with Incurable Pancreatic Cancer

Yoshiyuki Yamaguchi; Yousuke Katata; Makoto Okawaki; Akira Sawaki; Masahiro Yamamura


Kawasaki medical journal | 2014

Adoptive immunotherapy using autologous lymphocytes activated ex vivo with antigen stimulation for patients with incurable cancer

Makoto Okawaki; Katsuji Hironaka; Masahiro Yamamura; Yoshiyuki Yamaguchi

Collaboration


Dive into the Makoto Okawaki's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Akira Sawaki

Kawasaki Medical School

View shared research outputs
Researchain Logo
Decentralizing Knowledge